ADMA Biologics Inc vs Skyworks Solutions Inc — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Skyworks Solutions Inc trades at $69.59 (market cap $10.28B). The key difference: Skyworks Solutions Inc is far larger — about 4.6× ADMA Biologics Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SWKS | |
|---|---|---|
Market Cap | $2.22B | $10.28B |
Sector | Health | Technology |
52-Week High | $20.38 | $83.40 |
52-Week Low | $7.60 | $52.50 |
Enterprise Value | $2.29B | $10.16B |
Dividend Yield | — | 4.13% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
Skyworks Solutions (SWKS) trades at $68.17, down 0.9% today, with a bullish technical signal from moving averages and recent earnings beats in Q2 2026. The stock shows strong institutional buying interest and a 58% analyst buy rating, though revenue has declined from $5.5B in 2022 to $4.1B in 2025. The pending Qorvo combination and AI data center growth present strategic opportunities, but profitability margins have compressed, and a legal investigation adds near-term uncertainty.
The outlook is cautiously optimistic, supported by earnings consistency and diversification into automotive and AI markets, but investors face risks from integration execution, margin pressure, and regulatory scrutiny. The consensus price target of $66 suggests limited upside, requiring careful monitoring of merger progress and quarterly performance against expectations.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →